Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13024281 | 0.99 | GPR119 (0.39) | GPR119GPR183S1PR1GRM2S1PR5 | |
| SCHEMBL2904085 | 0.92 | GRM2 (0.40) | GPR119GPR183GRM2 | |
| SCHEMBL2893540 | 0.92 | GPR119 (0.38) | GPR119GPR183S1PR1GRM2S1PR5 | |
| SCHEMBL2891859 | 0.91 | HDAC4 (0.39) | GPR119GPR183 | |
| SCHEMBL2895563 | 0.91 | GPR119 (0.38) | GPR119GPR183S1PR1S1PR5S1PR4 | |
| SCHEMBL2891626 | 0.90 | GPR119 (0.38) | GPR119GPR183GRM2 | |
| SCHEMBL13024326 | 0.89 | GPR119 (0.39) | GPR119GPR183GRM2STAT3KCNH2 | |
| SCHEMBL13024325 | 0.89 | GPR119 (0.38) | GPR119GPR183GRM2 | |
| SCHEMBL2894005 | 0.89 | MTOR (0.40) | GPR119GPR183GRM2 | |
| SCHEMBL2888036 | 0.88 | HDAC4 (0.44) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2215078-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050523-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | GPR119, GIPR, GPR39 | GPR119 1/4885GPR183 30/4885S1PR1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.